Avidity Secures $100M Funding to Advance Treatments for Myotonic Dystrophy, DMD
News
Avidity Biosciences has obtained $100 million to advance its programs for muscle disorder therapies, including a potential Antibody Oligonucleotide Conjugates (AOC) treatment for myotonic dystrophy type 1 (MD1). Based on ... Read more